12:00 AM
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Basilea preclinical data

BAL27862 showed anti-proliferative activity in 8 NSCLC cell lines, as well as in 3 patient-derived NSCLC cell lines that were...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >